Literature DB >> 31756337

Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Adam L Halberstadt1, Muhammad Chatha2, Adam K Klein2, John D McCorvy3, Markus R Meyer4, Lea Wagmann4, Alexander Stratford5, Simon D Brandt6.   

Abstract

The ergoline d-lysergic acid diethylamide (LSD) is one of the most potent psychedelic drugs. 1-Acetyl-LSD (ALD-52), a derivative of LSD containing an acetyl group on the indole nitrogen, also produces psychedelic effects in humans and has about the same potency as LSD. Recently, several other 1-acyl-substitued LSD derivatives, including 1-propanoyl-LSD (1P-LSD) and 1-butanoyl-LSD (1B-LSD), have appeared as designer drugs. Although these compounds are assumed to act as prodrugs for LSD, studies have not specifically tested this prediction. The present investigation was conducted to address the gap of information about the pharmacological effects and mechanism-of-action of 1-acyl-substituted LSD derivatives. Competitive binding studies and calcium mobilization assays were performed to assess the interaction of ALD-52, 1P-LSD, and 1B-LSD with serotonin 5-HT2 receptor subtypes. A receptorome screening was performed with 1B-LSD to assess its binding to other potential targets. Head twitch response (HTR) studies were performed in C57BL/6J mice to assess in vivo activation of 5-HT2A (the receptor thought to be primarily responsible for hallucinogenesis). Finally, liquid chromatography/ion-trap mass spectrometry (LC/MS) was used to quantify plasma levels of LSD in Sprague-Dawley rats treated with ALD-52 and 1P-LSD. 1-Acyl-substitution reduced the affinity of LSD for most monoamine receptors, including 5-HT2A sites, by one to two orders of magnitude. Although LSD acts as an agonist at 5-HT2 subtypes, ALD-52, 1P-LSD and 1B-LSD have weak efficacy or act as antagonists in Ca2+-mobilization assays. Despite the detrimental effect of 1-acyl substitution on 5-HT2A affinity and efficacy, 1-acyl-substitued LSD derivatives induce head twitches in mice with relatively high potency. High levels of LSD were detected in the plasma of rats after subcutaneous administration of ALD-52 and 1P-LSD, demonstrating these compounds are rapidly and efficiently deacylated in vivo. These findings are consistent with the prediction that ALD-52, 1P-LSD and 1B-LSD serve as prodrugs for LSD. This article is part of the special issue entitled 'Serotonin Research: Crossing Scales and Boundaries'.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  5-HT(2A) receptor; LSD; Lysergamides; New psychoactive substances; Psychedelics

Mesh:

Substances:

Year:  2019        PMID: 31756337      PMCID: PMC9191647          DOI: 10.1016/j.neuropharm.2019.107856

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.273


  81 in total

1.  Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

Authors:  Javier González-Maeso; Noelia V Weisstaub; Mingming Zhou; Pokman Chan; Lidija Ivic; Rosalind Ang; Alena Lira; Maria Bradley-Moore; Yongchao Ge; Qiang Zhou; Stuart C Sealfon; Jay A Gingrich
Journal:  Neuron       Date:  2007-02-01       Impact factor: 17.173

2.  Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Neuropharmacology       Date:  2013-09-04       Impact factor: 5.250

3.  How LSD originated.

Authors:  A Hofmann
Journal:  J Psychedelic Drugs       Date:  1979 Jan-Jun

4.  Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.

Authors:  Adam L Halberstadt; Muhammad Chatha; Stephen J Chapman; Simon D Brandt
Journal:  J Psychopharmacol       Date:  2019-02-21       Impact factor: 4.153

5.  Pharmacological differentiation of human 5-HT1B and 5-HT1D receptors.

Authors:  S J Peroutka
Journal:  Biol Signals       Date:  1994 Sep-Oct

6.  Pharmacokinetics of methysergide and its metabolite methylergometrine in man.

Authors:  U Bredberg; G S Eyjolfsdottir; L Paalzow; P Tfelt-Hansen; V Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).

Authors:  Adam L Halberstadt; Landon M Klein; Muhammad Chatha; Laura B Valenzuela; Alexander Stratford; Jason Wallach; David E Nichols; Simon D Brandt
Journal:  Psychopharmacology (Berl)       Date:  2018-10-08       Impact factor: 4.530

8.  Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines.

Authors:  D L Nelson; V L Lucaites; J E Audia; J S Nissen; D B Wainscott
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

9.  N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.

Authors:  David E Nichols; M Flori Sassano; Adam L Halberstadt; Landon M Klein; Simon D Brandt; Simon P Elliott; Wolfgang J Fiedler
Journal:  ACS Chem Neurosci       Date:  2015-01-21       Impact factor: 4.418

10.  LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor.

Authors:  Donata Favretto; Giampietro Frison; Sergio Maietti; Santo Davide Ferrara
Journal:  Int J Legal Med       Date:  2006-02-23       Impact factor: 2.791

View more
  3 in total

1.  Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Benedikt Pulver; Kathleen Morton; Alexander Stratford; Geraldine Dowling; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2021-12-08       Impact factor: 3.234

2.  Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Benedikt Pulver; Hannes M Schwelm; Kyla Whitelock; Alexander Stratford; Volker Auwärter; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2022-05-29       Impact factor: 3.234

3.  Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Anna U Odland; Adam K Klein; Geraldine Dowling; Nicola M Dempster; Jason Wallach; Torsten Passie; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2020-04-20       Impact factor: 3.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.